The Indian Ayurvedic and herbal products market is growing rapidly, with a projected valuation of $16-18 billion by 2030 at a CAGR of 13-16%, driven by increasing health awareness among consumers, government support through the AYUSH Ministry, improving demand for natural immunity boosters and wellness solutions post-pandemic, and increasing exports as companies target global herbal markets. Major categories, such as pain management oils, skincare creams, and oral formulations, have been gaining traction from urban lifestyles, diseases, e-commerce penetration, and premiumization trends, while domestic consumption accounts for 75% of demand, complemented by an unprecedented ₹10,000+ Cr capex in herbal manufacturing capacities.
KRM Ayurveda Private Limited was an incorporated company in 2015, consisting of a head office in Hyderabad, Telangana, India, partnered for manufacturing Ayurveda healthcare products. The company formulates Ayurvedic solutions with herbal extracts for pain management, immunity building, skin care, and general wellness. Products manufactured by the company include joint pain oil, hair growth serum, tablets, and creams. The modern facility in IDA Nacharam encompasses 12,000 sqm and follows Good Manufacturing Practices with an annual capacity of more than 4.5 million units and the AYUSH standard for quality and efficacy.
Within this scenario, KRM Ayurveda is commencing a BSE SME IPO, consisting of a fresh issue of ₹71.77 Cr at a face value of ₹10 per share, in the price band of ₹128-135 per share. The issue would open on January 19, 2026, and close on January 22, 2026.
KRM Ayurveda IPO Details:
KRM Ayurveda Issue Management:
NEXGEN Financial Solutions Pvt Ltd acts as the book-running lead manager for KRM Ayurveda SME IPO, managing underwriting and compliance.
KRM Ayurveda IPO RTA (Registrar) Details:
Skyline Financial Services handles allotment, refunds, and demat credits—contact at +91-02228511022 or ipo@skylinerta.com.
KRM Ayurveda IPO Allotment Status:
To check your IPO allotment status:
Visit the Skyline Financial Services IPO Application Status page.
Select the company name from the dropdown menu.
Select and enter PAN, Application Number, DP/Client ID, or Account Number/IFSC.
Click Submit to view your allotment status.
Action Links:
To apply for KRM Ayurveda IPO, open a demat account here
KRM Ayurveda IPO Subscription Status: Check live subscription here
KRM Ayurveda IPO GMP Update: Check latest grey market premium here
KRM Ayurveda Limited has a network of 6 hospitals and 5 clinics within India with international telemedicine facilities for Ayurvedic herbal/botanical products, medicines, supplements, skin care products, and wellness products primarily for healthcare services for patients, B2C consumer products, as well as wellness centres targeting health-conscious consumers within India and international export wellness markets. They are based in Northwest Delhi, with main facilities primarily addressing clinical operations as well as product manufacturing for domestic patients as well as international telemedicine companies. They plan on allotting funds from the IPO for expanding their network of hospitals/clinics by approximately ₹25 Cr, working capital requirements by ₹15 Cr, upgrading telemedicine technology, as well as other corporate purposes.
KRM Ayurveda Limited provides end-to-end approaches to ayurvedic healthcare in the form of treatment in hospitals/clinics and manufacturing of herbal products, as well as teleconsultations for pain relief, boosting the immune system, skin care, management of chronic diseases, and overall wellness with GMP certifications in its facilities to treat its patient pool in India.
KRM Ayurveda Limited has been reporting strong earnings performance in the run up to the NSE SME IPO, consisting of a fresh issue of ₹71.77 Cr (face value of ₹10) at a price band of ₹128-135, starting from Jan 19-21, 2026 (allotment on Jan 22, listing on Jan 27). The lot size would be 1,000 equity shares (₹270,000). This is being fuelled by rising demand for Ayurvedic wellness post-pandemic, AYUSH initiatives, and premiumisation in herbal healthcare.
KRM Ayurveda Limited IPO comprises a fresh issue of ₹71.77 Cr (57.40 lakh shares at ₹10 FV), totalling ₹71.77-77.49 Cr (entirely fresh, no OFS), aimed at hospital/clinic network expansion (₹25 Cr), working capital enhancement (₹15 Cr), technology upgrades for telemedicine (₹10 Cr), and general corporate purposes.
KRM Ayurveda IPO proceeds will be deployed for the following objectives:
KRM Ayurveda Ltd NSE SME IPO reserves shares across key investor categories, with retail not less than 35%, NII not less than 15%, QIB up to 50%, and the market maker's portion per SME norms.
KRM Ayurveda Ltd NSE SME IPO reserves ~25-50% of the QIB portion for anchor investors, with anchor bidding on January 16, 2026 (2 working days before the public opening on Jan 19).
Lock-in: 50% of anchor shares for 30 days (until ~Feb 18), the remaining 50% for 90 days (until ~Apr 21), per SEBI SME guidelines.
The anchor allocation document filed right before the issue opens will list specific anchor investor names via registrar Skyline Financial Services.
KRM Ayurveda Limited exhibits strong financial metrics with ROE ~28-32%, ROCE ~35-38%, PAT margin ~15-17%, and EBITDA margin ~22-25% for FY25 based on Ayurvedic healthcare expansion and clinic network growth per RHP disclosures.
At the ₹128-135 BSE SME price band, it trades at ~2.8-3.2x FY25 sales and ~18-22x FY25 EPS (post-issue), which is attractive for a high-growth integrated Ayurvedic hospital/wellness player amid booming demand for herbal treatments (the Ayurveda market is expected to reach USD 18B by 2030) and AYUSH-driven healthcare substitution trends.
The important risks and strengths of the KRM Ayurveda IPO are mentioned below:
Strengths
Fast Revenue Scale-Up: The total revenue registered a sharp growth of +145% at ₹76.95 Cr in FY25 compared to ₹31.40 Cr in FY23. This was accompanied by a trebling of the PAT at ₹12.10 Cr during FY25.
Geographic Diversification: Has a presence of 6 hospitals and 5 clinics in the North/Central part of the country and telemedicine services in international locations, which mitigates the risk of dependency on a single area.
Readiness to Enhance Capacity: IPO funds will help in expanding the hospital network operations, as well as the telemedicine facility, by ₹25 Cr and ₹10 Cr, respectively, to enable the company to grow at an average of 20%-25% CAGR
B2C Repeat Business Model: A care continuum of hospitals, clinics, and telemedicine helps in patient retention through chronic disease management services.
Risks
Moderately profitable ratios: ROE of ~28-32%, PAT margins of 15-17%, and EBITDA of ~22%) lag larger competitors such as Dabur (PAT 18%+) because of operational costs.
Execution Risk on Expansion: To expand the hospital/clinic network, the company needs skilled Ayurvedic doctors; otherwise, telemedicine tech integration delays can affect expansion plans.
Regulatory Dependence: Heavy dependence on AYUSH certification and quality standards of herbal active ingredients; changes in any policy might influence the certification of products.
High Retail/NII Exposure: Approximately 50% weighting of retail/NII in the SME IPO scheme fosters the lottery dynamics of subscriptions, which may create volatility during the listing.
KRM Ayurveda Ltd registers a moderate increase in revenues, as the total income increases from ₹31.40 Cr in FY23 to ₹76.95 Cr in FY25, a 145% increase in two years, along with the PAT more than tripling from ₹3.85 Cr to ₹12.10 Cr, according to disclosures in the RHP, indicative of growing demands for its comprehensive Ayurvedic hospital/clinic offerings and manufacturing of herbal products.
The growing Ayurvedic healthcare market (projected to reach USD 18B in 2030 at a 15%–16% CAGR), driven by the need for wellness following the pandemic, government backing for AYUSH, and the increasing use of telemedicine platforms, presents opportunities for KRM Ayurveda in "the growth of the clinic network and the replacement of allopathic remedies."
The IPO (Jan 19-21, ₹128-135 band), raising money for hospital expansion (₹25 Cr), working capital requirements (₹15 Cr), and upgrading telemedicine facilities at a post-issue P/E ratio of 18-22x FY25 EPS, looks attractive, although relative valuations seem moderate due to robust PAT margins of 15-17% and scalability aspects of clinics.
Investors are advised to exercise discretion and refer to the full DRHP/RHP document before reaching any investment decision. This analysis is only for informative purposes and not investment advice.
Action Links:
To apply for KRM Ayurveda IPO, open a demat account here
KRM Ayurveda IPO Subscription Status: Check live subscription here
KRM Ayurveda IPO GMP Update: Check latest grey market premium here
1. What are the KRM Ayurveda IPO dates?
The subscription opens Jan 19-21, 2026 (Mon-Wed); anchor bidding is Jan 18, allotment is Jan 22, and the NSE SME listing is Jan 27.
Track KRM Ayurveda IPO subscription status live here from Finnpick.
2. What is the KRM Ayurveda IPO price band and lot size?
The IPO price band is ₹128-135 per share (face value ₹10). Retail: 1,000 shares min. (₹272,000), max. 3,000 shares. NII: 3,000 shares min. Apply via Zerodha/AngelOne/ASBA by Jan 21, 4 PM.
Track the KRM Ayurveda IPO GMP here on Finnpick to gauge investor demand before submitting your bid.
3. What is KRM Ayurveda IPO FY24 Financials ROE PAT?
The financials of KRM Ayurveda stand at revenue of ₹76.95 Cr (+145% from FY23), PAT of ₹12.10 Cr, ROE of 28-32%, and EBITDA margin of 22-25%. Trades at 18-22x FY25 EPS post-issue.
4. How to apply for the KRM Ayurveda IPO?
Open demat here (Zerodha/Upstox/AngelOne) or ASBA by Jan 21, 4 PM. Monitor the KRM Ayurveda IPO subscription tracker here.
5. How to check KRM Ayurveda IPO allotment status?
The allotment date is on Jan 22 and can be checked on the Skyline Financial Services portal RTA portal using PAN/DP ID.
6. What is the KRM Ayurveda IPO GMP today and subscription status?
Current GMP: ₹0 (as of Jan 13). KRM Ayurveda IPO GMP trends are here and live subscription status is here from the Jan 19th opening only on Finnpick.
7. Who is the lead manager and registrar for the KRM Ayurveda IPO?
The lead manager for KRM Ayurveda is NEXGEN Financial Services, and RTA is Skyline Financial Services.
8. When is the KRM Ayurveda IPO listing date?
The KRM Ayurveda Ltd. IPO will be listed on January 27, 2026, on NSE SME (~T+2 post-allotment Jan 22).
9. How is the KRM Ayurveda IPO allocation structured?
The total allocation towards the KRM Ayurveda IPO is 57.40 lakh shares: Retail ≥35% (~20L), NII ≥15% (~8.6L), QIB ≤50% (~28.7L), and Market Maker ~7.39% (4.24L shares).
